Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTLT Catalent

休市中 12-20 16:00:00 EST

63.48

+0.00

0.00%

最高63.48	最低63.48	成交量0.00
今开63.48	昨收63.48	日振幅0.00%
总市值115.22亿	流通市值114.51亿	总股本1.82亿
成交额0.00	换手率0.00%	流通股本1.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTLT","market":"US","secType":"STK","nameCN":"Catalent","latestPrice":63.48,"timestamp":1734728400000,"preClose":63.48,"halted":0,"volume":0,"delay":0,"floatShares":180392022,"shares":181511586,"eps":-2.280772,"marketStatus":"休市中","marketStatusCode":7,"change":0,"latestTime":"12-20 16:00:00 EST","open":63.48,"high":63.48,"low":63.48,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.280772,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1406779200000,"adjPreClose":63.48,"adrRate":0,"volumeRatio":0},"requestUrl":"/m/hq/s/CTLT/tweets","defaultTab":"tweets","newsList":[{"id":"2492186280","title":"诺和诺德控股公司以 165 亿美元完成对康泰伦特的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2492186280","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492186280?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:04","pubTimestamp":1734530697,"startTime":"0","endTime":"0","summary":"诺和诺德控股公司以 165 亿美元完成对康泰伦特的收购路透12月18日 - 诺和诺德控股公司（Novo Holdings）周三宣布，已完成对康泰伦特CTLT.N的165亿美元收购，这家合同药品生产商在几天前宣布，所有监管成交条件均已满足。  诺和诺德是丹麦制药商诺和诺德NOVOb.CO的控股股东，该公司生产GLP-1注射减肥药Wegovy。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4S3NJ10F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT","BK4007","BK4588","BK4530","BK4585"],"gpt_icon":0},{"id":"2491914926","title":"BUZZ--美国股票走势-诺和诺德、特斯拉、微策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2491914926","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491914926?lang=zh_cn&edition=full","pubTime":"2024-12-16 22:15","pubTimestamp":1734358514,"startTime":"0","endTime":"0","summary":"nL4N3NH0QL  ** Checkpoint Therapeutics Inc CKPT.O:BUZZ--该公司的皮肤癌药物获得美国食品和药物管理局批准后股价上涨。nL4N3NH0QI  ** NetApp NTAP.O:BUZZ - JPM将其评级上调至 \"增持\"，原因是人工智能引领的增长将改善IT预算。nL4N3NH0R7  ** 霍尼韦尔国际HON.O:BUZZ - 公司称考虑分拆航空业务，股价上涨。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4T3NH10L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","LU0130102774.USD","CTLT","LU0211327993.USD","MSTR","BK4555","BHVN","HON","CKPT","LU0070302665.USD","TSLA","LU1917777945.USD","LU0976567544.SGD","LU0053671581.USD","LU0417517546.SGD","LU1496350171.SGD","LU0011850046.USD","IE0034235188.USD","LU1145028129.USD","NTAP","BK4596","LU2237443465.HKD","BK4533","LU0496365809.HKD","BK4524","LU0980610538.SGD","LU1084165304.USD","LU1894683348.USD","PLBY","LU1670628061.USD","CBRE","LU1861558580.USD","BK4146","IE00BDCRKT87.USD","FBIO","MAS","BK4534","CPRI","LU2552382215.SGD","TSYW.SI","F","NKE","LU1244550221.USD","LU0234572021.USD","LU0971096721.USD","VRDN","LU1670627923.USD"],"gpt_icon":1},{"id":"2491667185","title":"BUZZ--美国股票走势-NetApp、霍尼韦尔、世邦魏理仕集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2491667185","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491667185?lang=zh_cn&edition=full","pubTime":"2024-12-16 20:14","pubTimestamp":1734351295,"startTime":"0","endTime":"0","summary":"nL4N3NH0QL  ** Checkpoint Therapeutics CKPT.O：BUZZ--该公司的皮肤癌药物获得美国食品和药物管理局批准后股价上涨。nL4N3NH0R7  ** 霍尼韦尔国际HON.O:BUZZ - 公司称考虑分拆航空业务，股价上涨。nL4N3NH0Q5  ** Edgewise Therapeutics EWTX.O:BUZZ - 因遗传疾病药物达到中期研究目标而上涨 nL4N3NH0SQ  ** 世邦魏理仕集团CBRE.N:BUZZ - 在摩根大通将其评级上调至 \"增持 \"后上涨 nL4N3NH0TA (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nL4T3NH0UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","LU1267930490.SGD","CTLT","MSTR","LU2413666004.HKD","LU0154245756.USD","LU1721427968.SGD","HON","IE00BFXG1179.USD","CKPT","LU1668664300.SGD","TSLA","LU0348723411.USD","LU0823414478.USD","IE00BZ1G4Q59.USD","BK4504","LU2413665964.HKD","IE00B3S45H60.SGD","LU0234570918.USD","NTAP","IE00B1BXHZ80.USD","BK4566","LU1620156130.USD","BK4596","LU0689472784.USD","LU0820561909.HKD","LU0316494557.USD","LU0980610538.SGD","LU1894683348.USD","LU0267386448.USD","LU1670628061.USD","BK4207","BK4574","CBRE","IE00BK4W5L77.USD","SG9999002224.SGD","LU0211326755.USD","LU2023250330.USD","BK4079","SG9999015986.USD","FBIO","CPRI","BK4581","TSYW.SI","IE00BK4W5M84.HKD","LU1244550577.SGD","MAS","LU1670627923.USD"],"gpt_icon":1},{"id":"2491409598","title":"诺和诺德控股公司称其 1650 亿美元康泰伦特交易的监管条件已满足","url":"https://stock-news.laohu8.com/highlight/detail?id=2491409598","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491409598?lang=zh_cn&edition=full","pubTime":"2024-12-15 00:27","pubTimestamp":1734193678,"startTime":"0","endTime":"0","summary":"路透12月14日 - 诺和诺德控股公司和康泰伦特公司周六表示，诺和诺德控股公司以165亿美元收购美国合同药品制造商康泰伦特公司的所有相关监管成交条件均已满足，并补充说交易有望在未来几天内完成。诺和诺德控股公司今年2月同意 ，收购康泰伦特公司，以提高广受欢迎的减肥药Wegovy的产量。根据交易条款，诺和诺德将以 110 亿美元的价格出售康泰伦特在意大利、比利时和美国的三家工厂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241214:nL4S3NF041:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTLT","BK4588","BK4530","BK4585"],"gpt_icon":0},{"id":"2489515092","title":"诺和诺德控股以 165 亿美元收购康泰伦特的交易获得欧盟反垄断批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2489515092","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489515092?lang=zh_cn&edition=full","pubTime":"2024-12-07 02:00","pubTimestamp":1733508022,"startTime":"0","endTime":"0","summary":"路透社布鲁塞尔12月6日 - 诺和诺德以165亿美元收购美国合同药品制造商康泰伦特的交易周五获得欧盟无条件反垄断批准，因为欧盟监管机构认为该交易不存在任何竞争问题。丹麦制药商诺和诺德NOVOb.CO的控股股东诺和诺德控股公司于今年2月宣布了这一交易。欧洲经济区指的是 27 个欧盟国家、冰岛、列支敦士登和挪威。Wegovy销售额的飙升使诺和诺德成为欧洲市值最高的公司。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL3S3N714Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4530","BK4007","BK4585","CTLT"],"gpt_icon":0},{"id":"2489490519","title":"肥胖症药物需求激增，礼来投资 30 亿美元扩建威斯康星工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2489490519","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489490519?lang=zh_cn&edition=full","pubTime":"2024-12-06 04:30","pubTimestamp":1733430616,"startTime":"0","endTime":"0","summary":"路透社12月5日 - 礼来公司LLY.N周四表示，它将投资30亿美元扩建今年早些时候在威斯康星州普莱森特普拉里购买的生产厂，以满足对其减肥药和糖尿病药物不断增长的需求。礼来公司表示，自 2020 年以来，该公司已累计投入超过 230 亿美元用于建设、扩建和购买生产基地。该公司表示，在威斯康星州收购、扩建、增购土地和毗邻仓库，使礼来在该基地的计划投资总额达到 40 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nL3S3N61H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0385154629.USD","CTLT","IE00B2B36J28.USD","LU1868836757.USD","BK4599","LU1064131342.USD","LU1974910355.USD","LU2468319806.SGD","SG9999015945.SGD","SG9999014880.SGD","SG9999018857.SGD","LU0097036916.USD","IE00BJJMRZ35.SGD","LU0354030438.USD","LU2237443978.SGD","LU0466842654.USD","LU2106854487.HKD","LU2361044865.SGD","LU2324357040.USD","LU1093756168.USD","LU0882574139.USD","LU0471298694.HKD","SGXZ57979304.SGD","LU0320765059.SGD","LU1551013425.SGD","LU2491050071.SGD","BK4533","LU0689472784.USD","SGXZ99366536.SGD","SGXZ51526630.SGD","LU2089984988.USD","LU0203201768.USD","LU0106261372.USD","LU2023250504.SGD","GB00BDT5M118.USD","LU1366192091.USD","LU2361045086.USD","LU2237443622.USD","LU2237443895.HKD","LU0943347566.SGD","SG9999013999.USD","SG9999015986.USD","LU2211815571.USD","LU2112291526.USD","BK4581","LLY","LU1623119135.USD","SGXZ81514606.USD","LU1551013342.USD","LU0708995401.HKD"],"gpt_icon":1},{"id":"2486474895","title":"欧盟或将无条件批准诺和诺德母公司收购Catalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2486474895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486474895?lang=zh_cn&edition=full","pubTime":"2024-11-25 07:52","pubTimestamp":1732492325,"startTime":"0","endTime":"0","summary":"据报道，欧盟委员会可能将无条件批准诺和诺德母公司Novo Holdings以165亿美元收购美国合同制药商Catalent 的交易。今年2月，Catalent同意以每股63.50美元的价格被Novo Holdings收购。Novo Holdings随后将向诺和诺德出售三个Catalent生产基地，这将有助于诺和诺德提高其畅销减肥药Wegovy的产量。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。截至周五收盘，Catalent涨2.21%，报60.98美元；诺和诺德涨2.37%，报105.06美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/25075245624283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4007","CTLT","BK4588","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","BK4532","LU1093756325.SGD","BK4530","LU1093756168.USD","NVO","LU0154236417.USD","BK4585"],"gpt_icon":1},{"id":"2485722009","title":"欧盟或将无条件批准诺和诺德(NVO.US)母公司收购Catalent(CTLT.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485722009","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485722009?lang=zh_cn&edition=full","pubTime":"2024-11-23 14:50","pubTimestamp":1732344657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，欧盟委员会可能将无条件批准诺和诺德 母公司Novo Holdings以165亿美元收购美国合同制药商Catalent的交易。今年2月，Catalent同意以每股63.50美元的价格被Novo Holdings收购。Novo Holdings随后将向诺和诺德出售三个Catalent生产基地，这将有助于诺和诺德提高其畅销减肥药Wegovy的产量。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。截至周五收盘，Catalent涨2.21%，报60.98美元；诺和诺德涨2.37%，报105.06美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4599","BK4585","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","BK4530","BK4532","CTLT","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","NVO","BK4007"],"gpt_icon":1},{"id":"2485294917","title":"消息人士称，诺和诺德控股公司将获得欧盟批准，以 160 亿美元收购康泰伦特公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2485294917","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485294917?lang=zh_cn&edition=full","pubTime":"2024-11-23 01:50","pubTimestamp":1732297818,"startTime":"0","endTime":"0","summary":"更新版 1-消息人士称，诺和诺德控股公司将获得欧盟批准，以 160 亿美元收购康泰伦特公司补充：欧盟执委会拒绝置评，诺和诺德和康泰伦特未立即回应置评请求，详情请见下表Foo Yun Chee/Maggie Fick路透布鲁塞尔/伦敦11月22日 - 一位直接了解此事的人士周五表示，诺和计划以165亿美元收购美国合同药品生产商 康泰伦特的交易将获得欧盟无条件反垄断批准，从而扫清了一个关键障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT1BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4530","BK4007","BK4585","CTLT","BK4588"],"gpt_icon":1},{"id":"2485029196","title":"消息人士称，欧盟反垄断监管机构将批准诺和诺德与康泰伦特价值 1650 亿美元的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2485029196","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485029196?lang=zh_cn&edition=full","pubTime":"2024-11-23 01:32","pubTimestamp":1732296766,"startTime":"0","endTime":"0","summary":"消息人士称，欧盟反垄断监管机构将批准诺和诺德与康泰伦特价值 1650 亿美元的交易路透布鲁塞尔/伦敦11月22日 - 一位直接了解此事的人士周五表示，欧盟反垄断监管机构将无条件批准诺和诺德以165亿美元收购康泰伦特的计划。诺和诺德是丹麦制药商诺和诺德NOVOb.CO的控股股东，其大片减肥药Wegovy的利润使其成为欧洲市值最高的公司。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4T3MT1B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTLT","BK4585","BK4530","BK4588"],"gpt_icon":0},{"id":"2484647678","title":"BUZZ-巴克莱认为 2025 年欧盟制药业前景充满挑战，看好诺和诺德与阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2484647678","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484647678?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:44","pubTimestamp":1731926697,"startTime":"0","endTime":"0","summary":"BUZZ-巴克莱认为 2025 年欧盟制药业前景充满挑战，看好诺和诺德与阿斯利康11月18日 -  ** 巴克莱认为，2025年欧盟制药业的前景充满挑战，理由是防御性行业将出现宏观轮动。** 近期大型制药公司情绪低落，医疗保健行业以外的市场前景不断改善，这表明 2025 年欧盟制药业的表现不会优于市场。** 该经纪商更看好诺和诺德NOVOb.CO和阿斯利康AZN.L，对这两家公司保持 \"增持 \"评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP0OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","CTLT","IE0002141913.USD","LU0211327993.USD","SG9999001176.SGD","LU0640478417.SGD","SG9999001176.USD","IE0009355771.USD","LU0047473722.EUR","LU1983299246.USD","LU0889565080.SGD","LU1019634622.SGD","LU1019632923.USD","LU1267930813.SGD","LU2023251221.USD","LU0823399737.USD","LU1989772923.USD","IE0034235188.USD","LU0029864427.USD","IE00BFTCPJ56.SGD","LU0158827948.USD","LU0708994859.HKD","LU1051770623.HKD","LU0496365809.HKD","LU0957799991.USD","LU2114397693.USD","LU0661504455.SGD","LU0203347892.USD","AZN.UK","LU1487256676.USD","LU1989771016.USD","LU2089984988.USD","LU0823416689.USD","LU0889566641.SGD","LU0757432116.USD","LU1267930573.SGD","LU1057294990.SGD","LU0211326839.USD","LU1267930227.SGD","LU0122379950.USD","03165","LU1153584641.USD","LU0972486137.USD","LU0345777147.USD","LU0997586432.USD","LU2089284900.SGD","BK4585","LU1261432733.SGD","LU2091194634.USD","LU1481600234.SGD"],"gpt_icon":0},{"id":"2483340838","title":"欧盟监管机构就 165 亿美元交易质询诺和诺德和康泰伦特竞争对手","url":"https://stock-news.laohu8.com/highlight/detail?id=2483340838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483340838?lang=zh_cn&edition=full","pubTime":"2024-11-14 01:21","pubTimestamp":1731518461,"startTime":"0","endTime":"0","summary":"欧盟监管机构已将初步审查的截止日期定在 12 月 6 日。这项价值 165 亿美元的交易  于今年 2 月宣布，凸显了诺和诺德提高每周注射一次的 Wegovy 产量的决心。交易完成后，诺和诺德控股公司将以 110 亿美元的价格把康泰伦特在意大利、比利时和美国的三个灌装工厂出售给诺和诺德。诺和诺德控股公司、诺和诺德公司和康泰伦特公司最近都重申，他们预计这项交易将于今年年底完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0061475181.USD","LU0079474960.USD","LU0471298694.HKD","LU1093756325.SGD","BK4533","IE00BFTCPJ56.SGD","LU0456855351.SGD","BK4532","IE00BJLML261.HKD","LU0385154629.USD","LU0256863902.USD","LU0820561818.USD","LU0203202063.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU0943347566.SGD","LU1035775433.USD","LU0203201768.USD","LU0417517546.SGD","LU0708995401.HKD","LLY","IE0004445239.USD","IE00BJT1NW94.SGD","LU1064131342.USD","NVO","BK4534","LU0154236417.USD","LU0289739699.SGD","LU0058720904.USD","LU0820561909.HKD","LU0882574055.USD","IE0002141913.USD","LU0114720955.EUR","LU1057294990.SGD","LU0471298777.SGD","LU0689472784.USD","BK4007","LU0238689110.USD","IE00B4R5TH58.HKD","LU0106261372.USD","LU1069344957.HKD","LU0006306889.USD","IE0009355771.USD","LU1023059063.AUD","LU0109391861.USD","CTLT","LU0354030511.USD","LU0198837287.USD","LU1061106388.HKD"],"gpt_icon":1},{"id":"2481509482","title":"康泰伦特第一季度营收不及预期，与诺和控股的 165 亿美元交易即将完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2481509482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481509482?lang=zh_cn&edition=full","pubTime":"2024-11-05 21:21","pubTimestamp":1730812917,"startTime":"0","endTime":"0","summary":"诺和诺德的控股投资公司 Novo Holdings 于今年 2 月同意收购康泰伦特，以增加 Wegovy 的供应。背景 康泰伦特表示，该交易预计将于今年年底完成，之后母公司将以 110 亿美元的价格向诺和诺德出售这家合同制造商的三个关键灌装-成品工厂。数字 根据 LSEG 统计的数据，康泰伦特在截至 9 月 30 日的第一财季实现营收 10.2 亿美元，略低于分析师预计的 10.6 亿美元。药品和消费者健康部门的销售额为 5.63 亿美元，低于预期的 5.666 亿美元。康泰伦特季度调整后每股亏损 13 美分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTLT"],"gpt_icon":0},{"id":"2480798573","title":"欧盟将于12月6日前对诺和诺德作出裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=2480798573","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480798573?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:57","pubTimestamp":1730710637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德收购美国合同制药商Catalent。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。欧盟反垄断监管机构可以在有或没有补救措施的情况下批准这笔交易，也可以在有严重担忧的情况下展开为期4个月的全面调查。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"c8930b257377b3ad681bfe33e024f8d5","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104170309ab9de4d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4532","BK4588","NVO","BK4007","BK4530","IE00BKVL7J92.USD","CTLT","LLY","LU1093756325.SGD","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2480379492","title":"欧盟将于12月6日前对诺和诺德(NVO.US)收购Catalent(CTLT.US)作出裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379492","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379492?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:57","pubTimestamp":1730710637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，根据欧盟委员会网站周一发布的文件，欧盟反垄断监管机构将在12月6日之前决定是否批准诺和诺德收购美国合同制药商Catalent。文件显示，诺和诺德控股股东于10月31日向欧盟提交了批准该交易的请求。此次收购于今年2月宣布，突显了丹麦制药商诺和诺德提高其畅销减肥药Wegovy产量的努力。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。诺和诺德在肥胖和糖尿病药物市场的主要竞争对手礼来也表达了担忧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206296.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["CTLT","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","LU1093756325.SGD","LLY","LU1093756168.USD","BK4588","NVO","BK4532","LU0154236417.USD","BK4585","BK4530"],"gpt_icon":1},{"id":"2480320101","title":"欧盟反垄断监管机构将于 12 月 6 日前就诺和诺德收购康泰伦特一事做出决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2480320101","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480320101?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:54","pubTimestamp":1730706871,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透布鲁塞尔11月4日 - 据欧盟执委会网站周一发布的一份文件显示，欧盟反垄断监管机构将在12月6日前决定是否批准诺和诺德收购合同药品生产商康泰伦特  的交易。文件显示，诺和诺德  的控股股东于10月31日向欧盟提出了批准该交易的申请。欧盟反垄断机构既可以在采取或不采取补救措施的情况下批准该交易，也可以在严重关切的情况下展开长达四个月的全面调查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c8930b257377b3ad681bfe33e024f8d5","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4532","LU1093756168.USD","LU1093756325.SGD","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","CTLT","BK4530","BK4588","BK4585"],"gpt_icon":0},{"id":"2478262473","title":"赛诺菲首席财务官称不会受到诺和诺德康泰伦特交易的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2478262473","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478262473?lang=zh_cn&edition=full","pubTime":"2024-10-25 13:54","pubTimestamp":1729835660,"startTime":"0","endTime":"0","summary":"    路透法兰克福10月25日 - 赛诺菲  财务总监周五表示，该公司不会受到诺和诺德  控股股东收购合同药品生产商康泰伦特<Catalent    的决定的影响，并补充说这笔交易对其竞争对手是有意义的。\"赛诺菲首席财务官弗朗索瓦-格扎维埃-罗杰在第三季度财报发布后的媒体电话会议上说：\"他们迫切需要产能，所以这对他们来说是有意义的， 。他补充说，鉴于减肥药的需求非常旺盛，诺和诺德为获得产能付出了 \"非常沉重的代价\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU0823416689.USD","LU0672654240.SGD","LU1064131342.USD","IE00B2B36J28.USD","BK4585","LU0471298777.SGD","LU0094547139.USD","IE00B1BXHZ80.USD","NVO","LU1035775433.USD","LU0882574139.USD","LU0154236417.USD","LU0417517546.SGD","LU0256863902.USD","LU0096364046.USD","IE0004445239.USD","LLY","IE00BJT1NW94.SGD","LU0061475181.USD","LU0820561818.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","BK4516","BK4533","LU0456855351.SGD","LU0689472784.USD","BK4530","LU0106261372.USD","LU0006306889.USD","LU0943347566.SGD","LU0238689110.USD","LU0256863811.USD","LU0114720955.EUR","IE0009355771.USD","LU0385154629.USD","LU1061106388.HKD","LU1093756168.USD","IE00B4R5TH58.HKD","LU0466842654.USD","LU0203202063.USD","IE0002141913.USD","BK4007","LU0203201768.USD","IE00BK4W5L77.USD","BK4532","BK4534","CTLT","LU0354030511.USD"],"gpt_icon":0},{"id":"2477558597","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558597","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558597?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4T3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0321505868.SGD","CTLT","LU0211327993.USD","LU1061106388.HKD","SG9999001176.USD","BK4530","IE00BJJMRZ35.SGD","LU0047473722.EUR","BK4139","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","BK4550","LU0211328371.USD","IE00BJT1NW94.SGD","LU0823399737.USD","LU0868494617.USD","IE00BFTCPJ56.SGD","BK4566","LU0964806797.USD","LU1066051498.USD","BK4533","BK5011","LU0957799991.USD","LU0661504455.SGD","BK4007","AZN.UK","LU0058720904.USD","LU0289739699.SGD","PFE","LU0757432116.USD","SG9999002224.SGD","LU0211326755.USD","LU0310800965.SGD","LU0784385840.USD","LU0557290698.USD","LU0553294199.USD","GPCR","IE000M9KFDE8.USD","SG9999013999.USD","LU0122379950.USD","03165","VKTX","LU0972486137.USD","LU1066053197.SGD","LU1883839398.USD","LU0738911758.USD","SGXZ57979304.SGD","LU0345777659.USD","AMGN"],"gpt_icon":1},{"id":"2477558594","title":"更新版 4-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477558594","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477558594?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 4-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 11 和 12 段增加了诺和诺德的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官称，有关部门应阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1066053197.SGD","LU0321505868.SGD","LU0661504455.SGD","LU0738911758.USD","LU0823399737.USD","LU0964806797.USD","LU0557290698.USD","LU1883839398.USD","LU0553294199.USD","LU1061106388.HKD","AMGN","LU0289739699.SGD","LU0047473722.EUR","BK4139","BK5011","BK4007","LU0957799991.USD","IE00BJJMRZ35.SGD","BK4533","IE00BJT1NW94.SGD","GPCR","LU0310800965.SGD","SGXZ57979304.SGD","CTLT","SG9999013999.USD","IE00B19Z3B42.SGD","LU0211328371.USD","LU0211326755.USD","LU0211327993.USD","LU0882574055.USD","LU0784385840.USD","LU0868494617.USD","LU0058720904.USD","VKTX","LU0757432116.USD","PFE","AZN.UK","LU0345777659.USD","SG9999001176.USD","03165","IE00BLSP4452.SGD","BK4530","SG9999002224.SGD","LU1066051498.USD","IE00BFTCPJ56.SGD","LU0122379950.USD","BK4566","IE000M9KFDE8.USD","LU0972486137.USD"],"gpt_icon":1},{"id":"2477539245","title":"更新版 3-罗氏公开反对收购药品制造商康泰伦特","url":"https://stock-news.laohu8.com/highlight/detail?id=2477539245","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477539245?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:22","pubTimestamp":1729678923,"startTime":"0","endTime":"0","summary":"更新版 3-罗氏公开反对收购药品制造商康泰伦特罗氏首席执行官：限制该领域的竞争并非好事 罗氏称受康泰伦特交易影响的不是自己，而是其他公司瑞士制药商与美国同行礼来一起表示反对第 6 段增加了首席执行官的评论，第 13 段增加了康泰伦特的评论Ludwig Burger. 路透法兰克福10月23日 - 制药巨头罗氏ROG.S.的首席执行官说，有关部门应该阻止诺和诺德的控股股东收购合同药品生产商康泰伦特CTLT.N.，因为这可能会打击蓬勃发展的减肥药行业的竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nL4S3LZ15P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IE00B2B36J28.USD","LU0557290698.USD","LU0949170772.SGD","LU0972486137.USD","LU1057294990.SGD","03165","LU0052756011.USD","BK5011","BK4568","LU0225284248.USD","LU0969580561.USD","GPCR","IE00BJT1NW94.SGD","AMGN","BK4566","PFE","LU0109394709.USD","LU0211326755.USD","IE00BJJMRZ35.SGD","LU0128525689.USD","LU0320765992.SGD","LU0345777659.USD","SG9999002232.USD","BK4139","LU0203345920.USD","LU0011850046.USD","LU0234572021.USD","BK4530","IE000M9KFDE8.USD","LU0122379950.USD","LU0310800379.SGD","LU0114720955.EUR","LU0203347892.USD","LU0792757196.USD","LU0211327993.USD","LU0963555726.SGD","AZN.UK","LU0170899867.USD","LU0949170426.SGD","VKTX","LU0985481810.HKD","LU1061106388.HKD","LU0708994859.HKD","IE0002141913.USD","BK4007","LU0128525929.USD","LU0321505439.SGD","CTLT","LU0526926950.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://catalent.com","stockEarnings":[{"period":"1week","weight":0.0065},{"period":"1month","weight":0.0759},{"period":"3month","weight":0.058},{"period":"6month","weight":0.1235},{"period":"1year","weight":0.446},{"period":"ytd","weight":0.4129}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Catalent, Inc.是全球领先的药物先进递送技术和开发制造解决方案提供商；蛋白质、细胞和基因治疗生物制品以及消费健康产品。该公司的口服、注射、细胞和基因治疗以及细胞和呼吸输送技术解决了制药行业的全面多样性，包括小分子；蛋白质、细胞和基因治疗生物制品；以及消费健康产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.058226},{"month":2,"riseRate":0.6,"avgChangeRate":0.038189},{"month":3,"riseRate":0.4,"avgChangeRate":0.009076},{"month":4,"riseRate":0.6,"avgChangeRate":0.013795},{"month":5,"riseRate":0.5,"avgChangeRate":0.014479},{"month":6,"riseRate":0.6,"avgChangeRate":0.020877},{"month":7,"riseRate":0.8,"avgChangeRate":0.082712},{"month":8,"riseRate":0.636364,"avgChangeRate":0.009563},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.037618},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.028945},{"month":11,"riseRate":0.636364,"avgChangeRate":0.013867},{"month":12,"riseRate":0.545455,"avgChangeRate":0.006017}],"exchange":"NYSE","name":"Catalent","nameEN":"Catalent"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Catalent(CTLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Catalent,CTLT,Catalent股票,Catalent股票老虎,Catalent股票老虎国际,Catalent行情,Catalent股票行情,Catalent股价,Catalent股市,Catalent股票价格,Catalent股票交易,Catalent股票购买,Catalent股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Catalent(CTLT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Catalent(CTLT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}